Cargando…

OMRT-15. Multidisciplinary management of non-small cell lung cancer patients with leptomeningeal metastasis in the TKI era

BACKGROUND: leptomeningeal metastasis (LM) is a devastating scenario in patients with non-small cell lung cancer (NSCLC), with an estimated median overall survival (OS) of 4–6 months from diagnosis. Several studies have clarified the prognosis of treatment modalities after LM. However, just a few st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Kuan-Yu, Huang, Abel Po-Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255445/ http://dx.doi.org/10.1093/noajnl/vdab070.039

Ejemplares similares

OMRT-8. Precision targeting of cellular pathways with complementary diagnostics
por: Siddaway, Robert, et al.
Publicado: (2021)

OMRT-11. The effect of microenvironment on glioblastoma stem cells therapeutic resistance
por: Turnsek, Tamara Lah, et al.
Publicado: (2021)

OMRT-14. Small molecule circadian clock compounds exhibit potential as a novel therapy paradigm for glioblastoma
por: Chan, Priscilla, et al.
Publicado: (2021)

OMRT-6. Optimizing MDM2 inhibition for the treatment of high-grade glioma
por: Rendo, Veronica, et al.
Publicado: (2021)

OMRT-5. Therapy-induced reprogramming drives glioma vascular transdifferentiation and recurrence
por: Muthukrishnan, Sree Deepthi, et al.
Publicado: (2021)

OMRT-7. Angiogenesis inhibitors strongly synergize with therapeutics targeting tumor metabolism
por: Khadka, Sunada
Publicado: (2021)

OMRT-12. Nanoparticle-based CRISPR-Cas9 delivery for anti-glioblastoma immunotherapy
por: Aguilar, Rocio, et al.
Publicado: (2021)

OMRT-1. Cannabidiol converts NFKB into a tumor-suppressor in glioblastoma with defined antioxidative properties
por: Volmar, Marie, et al.
Publicado: (2021)

OMRT-13. Delivery of Ubidecarenone (BPM 31510) to mitochondria effectuates metabolic reprogramming and redox activated apoptosis in Glioblastoma
por: Sarangarajan, Rangaprasad, et al.
Publicado: (2021)

OMRT-9. Effect of Pre-Operative Stereotactic Radiosurgery on Brain Metastasis: Analysis of DNA and RNA Genomic Profiles from Phase-II Clinical Trial NCT03398694
por: Shireman, Jack, et al.
Publicado: (2021)

OMRT-2. Liquid biopsy for patient stratification and monitoring of dacomitinib clinical trial in patients with EGFR amplified recurrent glioblastoma
por: Yekula, Anudeep, et al.
Publicado: (2021)

OMRT-3. Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment
por: Varn, Frederick, et al.
Publicado: (2021)

41. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS
por: Le Rhun, Emilie, et al.
Publicado: (2020)

40. AN UPDATE ON THE DEVELOPMENT OF A NEW TOOL TO ASSESS RESPONSE IN LEPTOMENINGEAL METASTASIS
por: Weller, Michael, et al.
Publicado: (2020)

NEIM-01 INCIDENCE AND DIAGNOSTIC TECHNIQUES FOR LEPTOMENINGEAL DISEASE IN PATIENTS WITH BRAIN METASTASIS
por: Henry, Katie, et al.
Publicado: (2022)

MET-8 Chemotherapy alone for brain metastases from small cell lung cancer -comparison with EGFR-TKI-
por: Iuchi, Toshihiko, et al.
Publicado: (2021)

21. A PHASE II TRIAL OF COMPREHENSIVE TREATMENT BASED ON RADIOTHERAPY IN LEPTOMENINGEAL METASTASIS
por: Yang, Siran, et al.
Publicado: (2020)

SPCR-02 NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS TREATED WITH PROTON CRANIOSPINAL IRRADIATION
por: Correa, Denise, et al.
Publicado: (2022)

ETMM-03. CANCER CELLS DEPLOY LIPOCALIN- 2 TO COLLECT LIMITING IRON IN LEPTOMENINGEAL METASTASIS
por: Chi, Yudan, et al.
Publicado: (2021)

BSCI-08 NEURONAL MIMICRY PROMOTES BREAST CANCER LEPTOMENINGEAL METASTASIS FROM BONE MARROW
por: Whiteley, Andrew, et al.
Publicado: (2022)

LMD-15. Beyond cytologY - A single institution experience using CNSide(TM) for diagnosing and monitoring treatment response in Non-Small Cell Lung Cancer patients with Leptomeningeal Carcinomatosis (LMC)
por: Akerley, Wallace, et al.
Publicado: (2021)

58. CLINICAL PRESENTATION AND IMAGING CHARACTERISTICS OF LEPTOMENINGEAL CARCINOMATOSIS (LC) IN PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)
por: Eastman, Boryana, et al.
Publicado: (2020)

MMAP-04 CYTOTOXIC, TUMOR-HOMING INDUCED NEURAL STEM CELLS AS AN ADJUVANT TO RADIATION IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER LEPTOMENINGEAL METASTASES
por: Mercer-Smith, Alison, et al.
Publicado: (2022)

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
por: Yufen, Xu, et al.
Publicado: (2016)

LMD-10. The role of immune checkpoint inhibitors in leptomeningeal disease: a systematic review
por: Palmisciano, Paolo, et al.
Publicado: (2021)

LMD-22. Clinicopathological spectrum of leptomeningeal metastases: A 3 year retrospective study
por: Pahwa, Saloni, et al.
Publicado: (2021)

LMD-21. Headache Improvement Predicts Survival after CSF diversion in Leptomeningeal Disease
por: Robin, Adam, et al.
Publicado: (2021)

OTME-17. Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases
por: Smalley, Inna, et al.
Publicado: (2021)

56. TUMOR-HOMING STEM CELL THERAPY INHIBITS THE PROGRESSION OF BREAST CANCER LEPTOMENINGEAL CARCINOMATOSIS
por: Jiang, Wulin, et al.
Publicado: (2020)

11. ASSOCIATION OF TUMOR EXPOSURE TO CEREBROSPINAL FLUID SPACES TO LEPTOMENINGEAL DISEASE IN PATIENTS WITH BRAIN METASTASES
por: Patel, Kunal, et al.
Publicado: (2020)

LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes
por: Bander, Evan D, et al.
Publicado: (2021)

LMD-19. Anatomic and Surgical Factors Predict Development of Leptomeningeal Disease in Patients with Metastatic Melanoma
por: Lowe, Stephen, et al.
Publicado: (2021)

LMD-06. A NSCLC patient with leptomeningeal metastasis harboring rare EGFR mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report
por: Wang, Hui, et al.
Publicado: (2021)

LMD-18. Detection and serial monitoring of CSF ctDNA in breast cancer leptomeningeal disease (BCLM)
por: Fitzpatrick, Amanda, et al.
Publicado: (2021)

LMD-14. Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome ((186)RNL) for leptomeningeal metastases
por: Guerra-Garcia, Maria, et al.
Publicado: (2021)

LMD-09. Outcomes and symptom benefit from palliative radiotherapy for leptomeningeal disease in breast cancer patients
por: Takayesu, Jamie, et al.
Publicado: (2021)

Advances in the diagnosis, evaluation, and management of leptomeningeal disease
por: Sener, Ugur, et al.
Publicado: (2021)

LMD-04. FLAIR hyperintensity along the brainstem surface in leptomeningeal metastases: a case series and literature review
por: Mitsuya, Koichi, et al.
Publicado: (2021)

LMD-12. Ubiquitin Conjugating Enzymes promote leptomeningeal dissemination and decrease survival in patients with brain metastatic disease
por: Paisana, Eunice, et al.
Publicado: (2021)

23. RETROSPECTIVE REVIEW OF ADULT PATIENTS WITH LEPTOMENINGEAL DISEASE SECONDARY TO MELANOMA AT MOFFITT CANCER CENTER: DIAGNOSIS, TREATMENT AND OUTCOMES
por: Pina, Yolanda, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_373e2149b56uv05oih8suh1395